These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22318190)

  • 1. [Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?].
    Caamaño AG; Mateos LL; Fernández EF; Crespo PC; Valladares BT; Higuero PP; Castro AC
    Arch Esp Urol; 2012; 65(1):193-206. PubMed ID: 22318190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Salvage brachytherapy for prostate cancer biochemical recurrence after radiotherapy].
    Rubio AP; López IJ
    Arch Esp Urol; 2012; 65(1):145-57. PubMed ID: 22318185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy.
    Namiki S; Saito S; Tochigi T; Ioritani N; Terai A; Arai Y
    Int J Urol; 2007 Mar; 14(3):186-91. PubMed ID: 17430252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage options for biochemical recurrence after primary therapy for prostate cancer.
    Bong GW; Keane TE
    Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
    Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
    J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease.
    Zietman AL; Dallow KC; McManus PA; Heney NM; Shipley WU
    Urology; 1996 Feb; 47(2):236-9. PubMed ID: 8607241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
    Tzou K; Tan WW; Buskirk S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment for recurrent localized prostate cancer.
    Van Der Poel HG; Moonen L; Horenblas S
    J Surg Oncol; 2008 Apr; 97(5):377-82. PubMed ID: 18360820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical recurrence after localized treatment.
    Amling CL
    Urol Clin North Am; 2006 May; 33(2):147-59, v. PubMed ID: 16631453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen recurrence after definitive therapy.
    Freedland SJ; Moul JW
    J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.